Revolutionizing Diagnosis and Treatment: Adaptive Biotechnologies’ Upcoming Business Update Conference Call and Webcast

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company has recently announced that it will be hosting a business update conference call and webcast on Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies is dedicated to harnessing the biology of the adaptive immune system to revolutionize disease diagnosis and treatment. The company believes that this powerful tool has not been fully utilized due to challenges in decoding it. Through its immune medicine platform, Adaptive Biotechnologies enables the decoding of the genetics of the adaptive immune system with scale, precision, and speed.

The company collaborates with biopharmaceutical companies to inform drug development and develop clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with the goal of developing personalized immune-driven clinical products for each patient.

For investors who have questions or need more information about this event or company updates, Karina Calzadilla can be reached at investors@adaptivebiotech.com . For media inquiries or interview requests with Adaptive Biotechnologies representatives please contact Erica Jones at media@adaptivebiotech.com .

Leave a Reply